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Dear Sir,  
Vitamin K, discovered in the 1930s, functions as a cofactor for 
the posttranslational carboxylation of glutamate residues (1). 
The vitamin K-epoxide reductase complex (VKOR) allows vit-
amin K epoxide to be converted back into reduced vitamin K. Its 
activity is the rate-limiting step of vitamin K-dependent protein 
gamma-carboxylation. Gamma-carboxylation is essential for the 
biological activity of clotting factors (factors II, VII, IX and X, 
and proteins C, S, and Z). Genetic and acquired disorders of 
some of these factors are linked to venous thromboembolism 
(VTE). Matrix Gla protein and bone Gla protein (osteocalcin), 
two vitamin K-dependent proteins involved in calcium home-
ostasis, have been implicated in the pathogenesis of athero-
sclerosis, myocardial infarction and stroke (2, 3). Moreover, 
VKOR has been implicated in angiogenesis, a process with an 
important role in cardiovascular disease (4). Studies of two 
families showing vitamin K-dependent clotting factor deficien-
cy type 2 (VKCFD2) permit to identify the VKOR subunit 1 
(VKORC1) gene. Another four patients resistant to vitamin K an-
tagonists (VKA) point to VKORC1 as a candidate locus at which 
certain mutations or polymorphisms confer resistance to phar-
macotherapy (5). VKORC1 as a target of coumarin-based drugs 
was confirmed in several single patients with coumarin resis-
tance, showing heterozygous mutations in VKORC1 exhibiting 
impaired coumarin inhibition (5, 6). Common VKORC1 poly-
morphisms have since been found to affect the VKA dose re-
sponse and warfarin dose requirements (7–10). The frequency of 
these polymorphisms differs among ethnic populations (8).  
Various nomenclature for VKORC1 haplotypes were pro-
posed : VKORC1*2 haplotype, strictly corresponds to the haplo-
type combination called “A” by Rieder’s study (7), while 
VKORC1*1, *3 and *4 haplotype, correspond to the haplotype 
combination called “B”. Two polymorphisms, the C1173T and 
G-1639A, are in complete linkage disequilibrium and can be 
used to distinguish between the haplotype combinations A and B. 
The simple genotyping of VKORC1 G-1639A or C1173T 
with the CYP2C9*3 polymorphism could predict a high risk of 
overdose before initiation of anticoagulation with acenocouma-
rol (9–12). Indeed, muted allele A or T (G-1639A or C1173T) ex-
plains about one third of the variability of the pharmacologic re-
sponse (37% of factor VII decrease and 30% of international nor-
malised ratio [INR] change) (9). Here we studied the functional 
promoter polymorphism of VKORC1 G-1639A (rs9923231) to 
identify the major VKORC1 haplotype 2 (group A of Rieder’s 
classification) (7) and “non VKORC1*2” haplotype (group B). 
The G allele of the G-1639A SNP corresponds to the group B 
VKORC1 haplotype and the A allele to the group A VKORC1 ha-
plotype. 
Two recent studies showed a link between VKORC1 haplo-
types and the risk of cardiovascular disease. The first, a Chinese 
case-control study, suggested that VKORC1 B/B haplotype was a 
major risk factor for coronary heart disease (CHD), stroke, and 
aortic dissection, probably through the role of osteocalcin in vas-
cular calcification (13). The second, a French case-control study, 
showed a protective effect of the VKORC1 A/A haplotype on 
VTE (14). However, several other studies have failed to show any 
association between the VKORC1 genotype and the risk of VTE, 
CHD or stroke (15, 16). To test the hypothesis that VKORC1- 
dependent effects on the coagulation cascade and vascular cal-
cification would contribute to susceptibility to vascular diseases, 
we investigated the previously unexplored association of 
VKORC1 A and B haplotypes with peripheral arterial disease 
(PAD). Conflicting findings prompted us to seek also a link be-
tween VKORC1 A and B haplotypes and VTE.  
We studied two matched case-control studies, namely the 
Pallas study (PAris Lower Limb Atherothrombosis Study) for 
PAD and the FARIVE study (FActeurs de RIsques et de récidives 
de la maladie thromboembolique VEineuse) for first episodes of 
VTE. All the participants gave their written informed consent, 
and the Paris-Cochin Ethics Committee approved the protocols. 
The PAD cases were consecutive Caucasian men under 70 years 
of age, who are described in detail elsewhere (17, 18). The FA-
RIVE study included men and women with a first proximal ve-
nous thrombosis and/or pulmonary embolism. For each case, 
age- and sex-matched controls were recruited among patients 
hospitalized during the same period with no history of arterial or 
venous thrombosis or cancer. 
VKORC1 A/B status was determined with the Taqman allelic 
discrimination assay (Applied Biosystems) targeting the dis-
criminant SNP G-1639A. The primers and probes (available on 
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Table 1: Association of the VKORC1 genotype with venous thromboembolism (VTE) and peripheral arterial disease (PAD). The G al-
lele of the G-1639A SNP corresponds to the group B VKORC1 haplotype of Rieder’s classification and the A allele to the group A VKORC1 haplotype. 
 Venous thromboembolism Severity of peripheral arterial  
disease 
2 vs. 1  
N=36 vs. 92 
3 vs. 1  
N=37 vs. 92 
RS 9923231 
G→A 
Controls 
N=257 (%) 
Cases 
N=257 (%) 
OR (95% CI) OR (95% CI) OR (95% CI) 
G allele 309 (60) 311 (61) 1 (Ref.) 1 (Ref.) 1 (Ref.) 
A allele 205 (40) 203 (39) 0.98 (0.77, 1.26) 1.12 (0.65, 1.95) 1.07 (0.62, 1.85) 
G/G genotype 090 (35.0) 100 (38.9) 1 (Ref.) 1 (Ref.) 1 (Ref.) 
G/A genotype 129 (50.2) 111 (43.2) 0.78 (0.54, 1.14) 1.46 (0.61, 3.47) 1.34 (0.57, 3.16) 
A/A genotype 038 (14.8) 046 (17.9) 1.09 (0.66, 1.82) 1.14 (0.38, 3.36) 1.05 (0.36, 3.06) 
G/A or A/A genotype 167 (65.0) 157 (61.1) 0.85 (0.60, 1.21) 1.35 (0.60, 3.02) 1.24 (0.56, 2.75) 
 
 
 
 
 
 
 
 
 
Peripheral arterial disease (overall) 
Controls 
N=303 (%) 
355 (59) 
251 (41) 
105 (34.7) 
145 (47.9) 
053 (17.5) 
198 (65.4) 
Cases 
N=165 (%) 
194 (59) 
136 (41) 
062 (37.6) 
070 (42.4) 
033 (20) 
103 (62.4) 
OR (95% CI) 
1 (Ref.) 
0.97 (0.73, 1.29) 
1 (Ref.) 
0.81 (0.53, 1.24) 
1.02 (0.58, 1.81) 
0.86 (0.57, 1.28) 
request) were chosen with Primer Express Software (Applied 
Biosystems, Courtaboeuf, France). STATA 8 software was used 
for statistical analyses. Odds ratios (ORs) and 95% confidence 
intervals (CIs) were estimated by means of conditional logistic 
regression. The genotype was modelled by assuming either a 
dominant model (1 or 2 copies of the minor allele) or a model 
with heterozygotes and homozygotes modelled separately. All 
analyses adjusted for the matching variables of age and gender. 
We adjusted only for matching factors, since acquired risk fac-
tors are not expected to confound genetic associations except 
through selection bias. 
The VKORC1 genotype frequencies in the VTE and PAD pa-
tients and controls are reported in Table 1. The VKORC1 genetic 
variants were in Hardy-Weinberg equilibrium. The observed fre-
quencies of minor allele A in cases and controls of the two 
studies ranged from 0.39 to 0.41. VKORC1 A were carried by 
61.1% of VTE cases and 65% of controls (OR=0.85; 95% CI: 
0.6–1.21). The VKORC1 genotype was not associated with VTE: 
the ORs were 0.78 (95% CI: 0.54–1.14) and 1.09 (95% CI: 
0.66–1.82), respectively, for VKORC1 A haplotype heterozygos-
ity and homozygosity. This confirmed that the VKORC1 geno-
type does not influence the risk of VTE (16). VKORC1 A was car-
ried by 62.4% of PAD cases and 65.4% of control subjects 
(OR=0.86, CI 0.57–1.28). The VKORC1 genotype was not as-
sociated with PAD: the ORs were 0.81 (95% CI: 0.53–1.24) and 
1.02 (95% CI: 0.58–1.28), respectively, for VKORC1 A haplo-
type heterozygosity and homozygosity. We also studied the pos-
sible influence of the VKORC1 genotype on the severity of PAD, 
categorized as follows: group 1: intermittent claudication (IC) 
with a walking distance above 100 m (N=92); group 2: IC with a 
walking distance below 100 m (N=36); and group 3: critical limb 
ischemia (N=37). Among cases, the genotype frequencies were 
not significantly different in group 2 compared with group 1 (OR 
1.12, 95% CI 0.69–1.83) or in group 3 compared with group 1 
(OR 0.99, 95% CI 0.61–1.62).  
VKORC1 could play a role in VTE or PAD by affecting 
gamma-carboxylation of vitamin K-dependent proteins, namely 
clotting factors in VTE and osteocalcin in PAD. In a Chinese 
study, the VKORC1 B/B haplotype was associated with 1.7– and 
1.8-fold increased risks of stroke and CHD, while VKORC1 A/A 
was associated with protection from VTE in a French population 
(14). However, these results were not confirmed in other Cau-
casian populations (15, 16). The VKORC1 A genotype frequen-
cies in the two case-control studies analyzed here are similar to 
those previously reported in European Caucasians (14, 15), but 
slightly higher than in a recent US study (16). However, differ-
ences in the geographic distribution of VKORC1 polymorphisms 
are unlikely to explain the lack of correlation with PAD and VTE 
observed here. Our study size was modest, and results were con-
sistent with a wide range of possible associations, as evidenced 
by the wide CIs. 
Our results suggest the absence of a clear association be-
tween VKORC1 polymorphisms that determine warfarin sensi-
tivity and the risk of VTE and PAD. Further investigations are 
needed to clarify the role of VKORC1 variants in the pathogen-
esis of arterial and venous thrombosis, in particular with impli-
cations of Gas6 or extra-hepatic Gla protein levels. Interactions 
with other candidate genes or local environmental factors might 
explain why VKORC1 gene variants are associated with arterial 
or venous thrombosis in certain populations. 
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